Incyte (NASDAQ: INCY)
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-11-01 | ||||||
REV |
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 0.750 | 1.010 | 0.2600 | ||||
REV | 815.170M | 911.397M | 96.227M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Incyte (NASDAQ: INCY) through any online brokerage.
Other companies in Incyte’s space includes: Legend Biotech (NASDAQ:LEGN), Sarepta Therapeutics (NASDAQ:SRPT), Exact Sciences (NASDAQ:EXAS), Neurocrine Biosciences (NASDAQ:NBIX) and Ionis Pharmaceuticals (NASDAQ:IONS).
The latest price target for Incyte (NASDAQ: INCY) was reported by Evercore ISI Group on Wednesday, August 3, 2022. The analyst firm set a price target for 78.00 expecting INCY to rise to within 12 months (a possible 8.09% upside). 18 analyst firms have reported ratings in the last year.
The stock price for Incyte (NASDAQ: INCY) is $72.16 last updated August 5, 2022, 8:00 PM UTC.
There are no upcoming dividends for Incyte.
Incyte’s Q3 earnings are confirmed for Tuesday, November 1, 2022.
There is no upcoming split for Incyte.
Incyte is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.